Paper22057701
β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.
Rodríguez-Baño J and 5 others. Clin Infect Dis, 2012. Cited by 291 papers, by iCite.
Cite this record
ConductScience Library. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Papers, record 22057701. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22057701
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Amoxicillin-Potassium Clavulanate Combination | Major topic |
| Anti-Bacterial Agents | Major topic |
| Bacteremia | Major topic |
| Escherichia coli Infections | Major topic |
| Penicillanic Acid | Major topic |
| beta-Lactamase Inhibitors | Major topic |
| Aged | |
| Aged, 80 and over | |
| Escherichia coli | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Multivariate Analysis | |
| Piperacillin | |
| Piperacillin, Tazobactam Drug Combination | |
| Proportional Hazards Models | |
| Prospective Studies | |
| Spain | |
| beta-Lactam Resistance |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT03891433 | Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae | Background | ClinicalTrials.gov | |
| NCT04699981 | Can the Relative Fecal Abundance of BLSE and the Digestive Microbiota be Predictive of the Risk of Infection in a Carrier Patient? | Results | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 22057699 | Can we really use ß-lactam/ß-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ß-lactamase-producing bacteria? | https://conductscience.org/library/papers/22057699 |
Source PubMed
Cited by148
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 291 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42867252 | Impact of inoculum effect on in vitro activity of intermittent and continuous piperacillin-tazobactam infusion against ESBL-producing Escherichia coli in a hollow-fiber infection model. | Microbiol Spectr | 2026 | https://conductscience.org/library/papers/42867252 | PubMed |
| 41857435 | Real-world outcomes and safety of colistin therapy in children with multidrug-resistant gram-negative infections: a nine-year experience. | Eur J Pediatr | 2026 | https://conductscience.org/library/papers/41857435 | PubMed |
| 41301622 | Antibiotics for Intra-Abdominal Infections: When, Which, How and How Long? | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/41301622 | PubMed |
| 41231468 | Female Sex and Mortality in Patients With Gram-Negative Bacteremia: A Systematic Review and Meta-Analysis. | JAMA Netw Open | 2025 | https://conductscience.org/library/papers/41231468 | PubMed |
| 41011196 | Boronate-Based Inhibitors of Penicillin-Binding Proteins: An Underestimated Avenue for Antibiotic Discovery? | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41011196 | PubMed |
| 40583993 | Escherichia coli producing AmpC DHA-1 bacteraemia in neutropenic leukemic patient: continuous infusion ceftazidime/avibactam as a carbapenem sparing regimen. | JAC Antimicrob Resist | 2025 | https://conductscience.org/library/papers/40583993 | PubMed |
| 40558193 | In Vitro Activity of Cefaclor/Beta-Lactamases Inhibitors (Clavulanic Acid and Sulbactam) Combination Against Extended-Spectrum Beta-Lactamase Producing Uropathogenic E. coli. | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/40558193 | PubMed |
| 40454310 | β-Lactam/β-Lactamase Inhibitor Combinations Non-Susceptible ESBL-Producing Enterobacteriaceae Bloodstream Infections: An Underestimated Clinical Entity. | Infect Drug Resist | 2025 | https://conductscience.org/library/papers/40454310 | PubMed |
| 39442132 | Optimization of antibiotic use in the intensive care unit: how we do it. | Crit Care Sci | 2024 | https://conductscience.org/library/papers/39442132 | PubMed |
| 38864641 | No improvement in mortality among critically ill patients with carbapenems as initial empirical therapy and more detection of multi-drug resistant pathogens associated with longer use: a post hoc analysis of a prospective cohort study. | Microbiol Spectr | 2024 | https://conductscience.org/library/papers/38864641 | PubMed |
| 38851757 | Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use. | World J Emerg Surg | 2024 | https://conductscience.org/library/papers/38851757 | PubMed |
| 38680606 | All-cause and Infection-attributable Mortality Amongst Adults With Bloodstream Infection-a Population-based Study. | Open Forum Infect Dis | 2024 | https://conductscience.org/library/papers/38680606 | PubMed |
| 38630105 | Microbiological Characteristics and Antibiotic Sensitivity in Patients with Nosocomial Spontaneous Bacterial Peritonitis Caused by Escherichia coli: A Multicenter Study. | Infect Microbes Dis | 2020 | https://conductscience.org/library/papers/38630105 | PubMed |
| 38534720 | Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and Pseudomonas aeruginosa. | Antibiotics (Basel) | 2024 | https://conductscience.org/library/papers/38534720 | PubMed |
| 38257978 | Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin-Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing Enterobacterales Secondary Bloodstream Infections: Findings from a Prospective Pilot Study. | Microorganisms | 2024 | https://conductscience.org/library/papers/38257978 | PubMed |
| 38197416 | Treatment, outcomes and characterization of pathogens in urinary tract infections caused by ESBL-producing Enterobacterales: a prospective multicentre study. | J Antimicrob Chemother | 2024 | https://conductscience.org/library/papers/38197416 | PubMed |
| 37148398 | Antibiotic stewardship in the ICU: time to shift into overdrive. | Ann Intensive Care | 2023 | https://conductscience.org/library/papers/37148398 | PubMed |
| 37104080 | Risk Factors for Bloodstream Infections Due to ESBL-Producing Escherichia coli, Klebsiella spp., and Proteus mirabilis. | Pharmacy (Basel) | 2023 | https://conductscience.org/library/papers/37104080 | PubMed |
| 36830273 | Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation. | Antibiotics (Basel) | 2023 | https://conductscience.org/library/papers/36830273 | PubMed |
| 36750600 | Retrospective analysis of drug resistance characteristics and infection related risk factors of multidrug-resistant organisms (MDROs) isolated from the orthopedics department of a tertiary hospital. | Sci Rep | 2023 | https://conductscience.org/library/papers/36750600 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22057701
GET https://conductscience.org/api/papers/v1/22057701/cited_by?page=2